Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study

• Published in: Journal of the European Academy of Dermatology and Venereology 2019-03, Vol.33 (3), p.553-559
• Main Authors: Deza, G., Notario, J., Lopez‐Ferrer, A., Vilarrasa, E., Ferran, M., del Alcazar, E., Carrascosa, J.M., Corral, M., Salleras, M., Ribera, M., Puig, L., Pujol, R. M., Vidal, D., Gallardo, F.
• Format: Article
• Language: English
• Subjects: Adult; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Biological Products - therapeutic use; Dermatologic Agents - adverse effects; Dermatologic Agents - therapeutic use; Female; Humans; Injection Site Reaction - etiology; Male; Middle Aged; Psoriasis - drug therapy; Retreatment; Retrospective Studies; Severity of Illness Index
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/jdv.15288

Background Ixekizumab (anti‐IL17A) is effective as treatment for moderate‐to‐severe plaque psoriasis, but real‐life data on effectiveness and safety are currently very limited. Objective To evaluate the efficacy and safety of ixekizumab in a cohort of real‐life plaque psoriasis patients. Methods Retrospective chart review of 100 patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab at seven Spanish dermatological centres. Results According to the as observed analysis, the percentage of patients achieving a 75% and 90% of reduction from the baseline score of Psoriasis Area and Severity Index (PASI) was 87.5%–50.0% at week 12–16; 88.3%–58.4% at week 24 and 82.9%–58.5% at week 52, respectively. The mean ± standard deviation (SD) score of PASI at baseline was 12.9 ± 9.2, and it declined rapidly after ixekizumab administration to 1.9 ± 4.0 (P